How human challenge trials can accelerate vaccine development

Human challenge studies provide more valuable information than animal challenge studies, which produce results that must be extrapolated in order to determine the impact on humans. They also allow for trials on a small participant pool that faces minimal risk of adverse outcomes, clinical complications or hospitalization. Finally, the small size of the trial reduces the financial risk of failure, as much less vaccine product is required for a human challenge trial than a Phase II clinical trial.

The effort to develop a vaccine to stem the tide of the COVID-19 pandemic provides a clear example of the importance of eliminating barriers to health care innovation.

In this environment, established commercial companies in the human challenges trial market, including hVIVO, can pioneer epidemic and pandemic disease modeling to accelerate the development of vaccines with proven efficacy. These firms can serve as valuable partners to the pharma and biotech industries by removing longstanding bottlenecks to innovation.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan spin-out Poolbeg Pharma to list on London market

Dublin-listed pharmaceutical services company Open Orphan will seek admission of its spin-out company Poolbeg Pharma to trade on the London Stock Exchange’s AIM, using the funds raised to meet the costs of the clinical trials for its flu treatment. Poolbeg Pharma, which

Open Orphan Plc

Open Orphan updates on demerger

Further to Open Orphan plc (LON:ORPH) announcement on 14 June 2021 in relation to the distribution in specie, the boards of Open Orphan and Poolbeg Pharma are pleased to announce Poolbeg’s intention to seek admission of its shares to trading on

Open Orphan Plc

Open Orphan Distribution in Specie and Notice of Results

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that, further to previous announcements, it proposes to make a

Open Orphan Plc

End-to-end Drug Development & Clinical Research services

Venn Life Sciences is an Integrated Drug Development Partner offering aunique combination of drug development expertise and clinical trialdesign and management. This enables us to create, plan and execute drugand medical device development programs effectively and seamlessly forour